Streetbeat News

Products Services

ABBV

COP

NVDA

VRTX

CNBC's 'Final Trades' featured Nvidia, Vertex Pharmaceuticals, ConocoPhillips, and AbbVie. Nvidia announced a 10-for-1 stock split, Vertex revealed positive data on CASGEVY™, ConocoPhillips was recommended due to its acquisition of Marathon Oil, and AbbVie reported positive trial results for mirvetuximab soravtansine.

Portfolio Pulse from Avi Kapoor

June 17, 2024 | 12:47 pm

EVAX

Evaxion Biotech announced the publication of data from its Phase 1 dose escalation study of EVX-01 in the 'Journal for ImmunoTherapy of Cancer,' showing a 67% objective response rate.

Portfolio Pulse from Benzinga Newsdesk

June 17, 2024 | 12:46 pm

CHRW

TFIN

Triumph Financial and C.H. Robinson have announced a strategic relationship to deliver innovative payment solutions to the transportation industry. C.H. Robinson will join the TriumphPay Network, enhancing payment experiences for brokers, shippers, factors, and carriers.

Portfolio Pulse from Benzinga Newsdesk

June 17, 2024 | 12:45 pm

VEV

Vicinity Motor Corp. (NASDAQ:VEV) has received an order for two Vicinity Classic Clean Diesel buses from the Town of Orangeville, Ontario, for delivery in 2025. Financial terms were not disclosed.

Portfolio Pulse from Benzinga Newsdesk

June 17, 2024 | 12:43 pm

AAN

KAVL

NDRA

NRIX

OVID

SCNI

TRNR

Shares of Nurix Therapeutics (NRIX) surged 12.1% in pre-market trading following positive clinical trial results. Other notable pre-market movers include Scinai Immunotherapeutics (SCNI), Interactive Strength (TRNR), ENDRA Life Sciences (NDRA), and The Aaron’s Company (AAN), which saw significant gains. Conversely, Ovid Therapeutics (OVID) and Kaival Brands Innovations (KAVL) experienced substantial declines.

Portfolio Pulse from Avi Kapoor

June 17, 2024 | 12:43 pm

TAK

Takeda Pharmaceutical Co Ltd (NYSE:TAK) announced that its anti-seizure treatment, Soticlestat, failed to meet primary endpoints in two Phase 3 studies for Dravet and Lennox-Gastaut syndromes. Despite some positive secondary outcomes, the primary goals were narrowly missed. Takeda plans to discuss the results with regulatory authorities.

Portfolio Pulse from Vandana Singh

June 17, 2024 | 12:41 pm

EVOK

Evoke Pharma (NASDAQ: EVOK) reports progress in its commercial strategy for GIMOTI, including expanded state Medicaid access and record monthly prescription fills in May 2024. The company also promoted Mark Kowieski to CFO.

Portfolio Pulse from Benzinga Newsdesk

June 17, 2024 | 12:41 pm

CEG

FUL

NVAX

SOFI

TWLO

VST

Jim Cramer provided his insights on various stocks during CNBC's 'Mad Money Lightning Round.' He recommended staying away from Twilio (TWLO) and Unity Software (U), while expressing a preference for Constellation Energy (CEG) over Vistra Corp. (VST). He also recommended H.B. Fuller (FUL) as a 'great little industrial company' and advised caution on SoFi Technologies (SOFI) and Novavax (NVAX).

Portfolio Pulse from Avi Kapoor

June 17, 2024 | 12:39 pm

ETHUSD

Crypto analyst Michaёl van de Poppe predicts a reversal in altcoin prices in the coming weeks, driven by potential Ethereum ETF approvals and easing dollar strength. Despite recent declines due to regulatory uncertainties and market events, Van de Poppe remains optimistic about a rebound.

Portfolio Pulse from Khyathi Dalal

June 17, 2024 | 12:38 pm

KNSA

Kiniksa Pharmaceuticals (NASDAQ:KNSA) is sponsoring the American Heart Association's initiative to improve the quality of care for recurrent pericarditis. The initiative aims to enhance diagnosis and management practices across 15 healthcare sites.

Portfolio Pulse from Benzinga Newsdesk

June 17, 2024 | 12:37 pm